

BIOTECH THERAPEUTIC DEVELOPMENT



PRODYNOV

Technology matured by



#PDT

#oncology

#Ovary

Prodynov is a third-generation photosensitizer (PS).
It targets folate receptors that are overexpressed in cancer cells of the ovary, liver, and pancreas.
The proof-of-concept conducted to date focuses on peritoneal carcinomatosis.


Under illumination from a dedicated light-delivery device, this photosensitizer exhibits a triple mechanism of action:

- Fluorescence-guided visualization of cancer cells to enable surgical removal
- Lysis of tumor cells that are not accessible surgically
- Activation of the immune system

Additional key features:

- Water-soluble, with higher efficacy than 5-ALA
- "Pre-GMP" synthesis in three steps, with a detailed protocol for the optimized synthetic route
- Analytical method for identification, quantification, and purity assessment
- Method for solubilization and pre-formulation
- ADME-Tox *in vitro* and *in vivo*, DMT, PK, efficacy demonstrated in mice and pigs

**Third-generation photosensitizer (PS)
for the treatment of cancers overexpressing
folate receptors (ovary, liver, pancreas)
using Photodynamic Therapy (PDT)**



PI : 1 Patent **TRL : POC In vivo (4/5)**

Partnership : Licensing

CONTACT SATT Nord

François-Xavier DENIMAL | Business Developer | francois-xavier.denimal@sattnord.fr